Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer

被引：5
|
作者：
Thomas, Lewis [1 ,2 ]
Baratchian, Mehdi [1 ]
Sharifi, Nima [1 ,2 ,3 ]
机构：
[1] Cleveland Clin, Lerner Res Inst, Genitourinary Malignancies Res Ctr, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Urol, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[3] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
EUROPEAN UROLOGY | 2020年 / 77卷 / 02期
关键词：
D O I：
10.1016/j.eururo.2019.07.037
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：156 / 157
页数：2
相关论文
共 50 条
  • [21] Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer
    Kang, Borui
    Mottamal, Madhusoodanan
    Zhong, Qiu
    Bratton, Melyssa
    Zhang, Changde
    Guo, Shanchun
    Hossain, Ahamed
    Ma, Peng
    Zhang, Qiang
    Wang, Guangdi
    Payton-Stewart, Florastina
    PHARMACEUTICALS, 2023, 16 (05)
  • [22] BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
    Luk, Iris Sze Ue
    Shrestha, Raunak
    Xue, Hui
    Wang, Yuwei
    Zhang, Fang
    Lin, Dong
    Haegert, Anne
    Wu, Rebecca
    Dong, Xin
    Collins, Colin C.
    Zoubeidi, Amina
    Gleave, Martin E.
    Gout, Peter W.
    Wang, Yuzhuo
    CLINICAL CANCER RESEARCH, 2017, 23 (06) : 1542 - 1551
  • [23] Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
    Graff, Julie N.
    Alumkal, Joshi J.
    Drake, Charles G.
    Thomas, George V.
    Redmond, William L.
    Farhad, Mohammad
    Cetnar, Jeremy P.
    Ey, Frederick S.
    Bergan, Raymond C.
    Slottke, Rachel
    Beer, Tomasz M.
    ONCOTARGET, 2016, 7 (33) : 52810 - 52817
  • [24] Biomarker Analysis of Men With Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer Treated With Pembrolizumab
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 15 - 16
  • [25] OVERCOMING RESISTANCE TO NK-MEDIATED LYSIS IN ENZALUTAMIDE-RESISTANT PROSTATE CANCER CELLS
    Dahut, Madeline
    Fousek, Kristen
    Horn, Lucas
    Qin, Haiyan
    Schlom, Jeffrey
    Palena, Claudia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A947 - A947
  • [26] COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRECLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER
    Toren, Paul
    Kim, Soojin
    Zoubeidi, Amina
    JOURNAL OF UROLOGY, 2016, 195 (04): : E813 - E814
  • [27] Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer
    Papageorgiou, Georgios Ioannis
    Skouteris, Nikolaos
    Kosma, Aikaterini
    Markouizou, Athina
    Charalampakis, Nikolaos
    REVIEWS ON RECENT CLINICAL TRIALS, 2023, 18 (02) : 146 - 155
  • [28] OVERCOMING ENZALUTAMIDE-RESISTANT WITH A NOVEL ANTI-AR PEPTIDE IN PROSTATE CANCER CELLS
    Zainfeld, Daniel
    Chen, Ruibao
    Thrasher, J. Brantley
    Li, Benyi
    JOURNAL OF UROLOGY, 2016, 195 (04): : E1095 - E1095
  • [29] Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
    Dahut, Madeline
    Fousek, Kristen
    Horn, Lucas A.
    Angstadt, Shantel
    Qin, Haiyan
    Hamilton, Duane H.
    Schlom, Jeffrey
    Palena, Claudia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [30] Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer
    Ye, Chen
    Chen, Yuan-Gui
    Qin, Sheng-Fei
    Tang, Shou-Yan
    Li, Song
    Shi, Min-Feng
    Zhou, Tie
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, 11 (05) : 643 - 658
12345